Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

The world's first inclined beam treatment room is open and treating patients at the ProCure Proton Therapy Center in Oklahoma City. The third of four treatment rooms at the Oklahoma Center is treating a wide range of tumors with proton therapy, an important alternative to X-ray radiation in treating cancer.

15 Apr 2010

New findings point to potential dysfunctional learning process in chronic pain patients

New research reveals why a stimulus that healthy human subjects perceive as a reward might be processed quite differently in the brains of humans suffering from chronic pain.

15 Apr 2010

MRI technology depicts women's anxiety of getting fat

A group of women in a new study seemed unlikely to have body image issues - at least their responses on a tried-and-true psychological screening presented no red flags.

15 Apr 2010

$SBUMC adds Toshiba Aquilion ONE \320-detector row CT system with pediatric imaging capabilities$

SBUMC adds Toshiba Aquilion ONE \320-detector row CT system with pediatric imaging capabilities

A new state-of-the art computed tomography (CT) scanner that provides physicians with precise images of internal organs with a single rotation of the gantry is now in operation at Stony Brook University Medical Center (SBUMC), adding to the hospital's advanced scanner technology.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Brain regions play a fundamental role in empathetic and violent situations

"Just as our species could be considered the most violent, since we are capable of serial killings, genocide and other atrocities, we are also the most empathetic species, which would seem to be the other side of the coin", Luis Moya Albiol, lead author of the study and a researcher at the UV, tells SINC.

15 Apr 2010

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

Albert Einstein College of Medicine of Yeshiva University has been awarded $750,000 by the John D. and Catherine T. MacArthur Foundation to study the impact of housing on the cardiovascular health of Latinos in the Bronx.

15 Apr 2010

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Tapeworm infections of the brain, which can cause epileptic seizures, appear to be increasing in Mexico and bordering southwestern states, Loyola University Health System researchers report.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair.

15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Second stage of pool laws will cost a precious buck to 70% pool owners

The Bligh Government yesterday released further changes in the pool safety laws and nearly 70% of all Gold Coast and Queensland homes with pools, including portable and inflatable ones will need to spend extra on upgrades.

14 Apr 2010

Foods that protect from Alzheimer’s

In a recent study researchers have revealed what we always knew - salads, fish, fruits and nuts are good for us. It says that these food combinations are related to a reduced risk of getting the dreaded brain and memory disease called Alzheimer’s disease. This study published in the online edition of the reputed journal Archives of Neurology also says that lesser the amount of high-fat dairy foods like butter etc. and red meats, the lesser is the risk of Alzheimer’s disease.

13 Apr 2010

CAS Medical Systems granted Japanese patent for LASER-SIGHT technology in FORE-SIGHT Oximeter

CAS Medical Systems, Inc. today announced that that the Japanese Patent Office has granted a new patent for the Company's LASER-SIGHT® technology used in the FORE-SIGHT® Oximeter.

13 Apr 2010

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.

13 Apr 2010

Brain News and Research

Further Reading

Opexa Therapeutics presents key efficacy data on Tovaxin

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

New findings point to potential dysfunctional learning process in chronic pain patients

MRI technology depicts women's anxiety of getting fat

SBUMC adds Toshiba Aquilion ONE \320-detector row CT system with pediatric imaging capabilities

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Brain regions play a fundamental role in empathetic and violent situations

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Researchers identify gene that appears to increase risk of Alzheimer's disease

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Study: New anti-cancer agents halt cancer metastasis

Second stage of pool laws will cost a precious buck to 70% pool owners

Foods that protect from Alzheimer’s

CAS Medical Systems granted Japanese patent for LASER-SIGHT technology in FORE-SIGHT Oximeter

Alkermes submits VIVITROL sNDA for opioid dependence

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News